ANGLE has completed a fundraising
October 2020 — ANGLE Plc has raised funds to develop the company.
ANGLE, through its subsidiaries, engages in providing products in cancer diagnostics and foetal health. Its main product is the Parsortix cell separation system, which can capture very rare cells from the blood.
Our role in the transaction
Oaklins Cavendish’s sister firm finnCap, based in the UK, in its role as nominated advisor and joint broker, lead the fundraising process from start to finish. During this process, the team initiated and advised on many aspects, including, among others, securing pre-commitments from cornerstone investors, deal structuring and the fundraise pricing and sizing.
Talk to the deal team
Related deals
Tandem has completed a voluntary public tender offer for the shares of Compagnia dei Caraibi
Tandem S.r.l. has completed a voluntary public tender offer for 25.99% of the shares in Compagnia dei Caraibi S.p.A.
Learn moreICOP has transferred its listing from Euronext Growth Milan to Euronext Milan
ICOP S.p.A. has transferred its listing from Euronext Growth Milan to Euronext Milan.
Learn moreRöntgeninstitut Aarau has been acquired by Evidia
The owners of Röntgeninstitut Aarau have sold the business to Evidia Group as part of their succession planning. The former owners will remain involved in the institute and support its future development alongside Evidia.
Learn more